Genmab A/S has received a $3.4 million milestone payment from GlaxoSmithKline related to the filing of the NDA to the Japanese Ministry of Health, Labor and Welfare (MHLW). The NDA is for Arzerra (ofatumumab) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.